Neurocrine Biosciences (NBIX) News Today → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free NBIX Stock Alerts $142.29 +0.38 (+0.27%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 9:51 PM | marketbeat.comBrown Advisory Inc. Raises Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Brown Advisory Inc. lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,113,413 shares of the company's stock after purchasinMay 18 at 5:32 AM | americanbankingnews.comMatt Abernethy Sells 15,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockMay 18 at 4:58 AM | americanbankingnews.comGary A. Lyons Sells 12,500 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockMay 18 at 12:31 AM | marketbeat.comFiera Capital Corp Raises Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Fiera Capital Corp boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 516,865 shares of the company's stock after acquiring an additional 5,497 sharMay 17 at 11:22 AM | insidertrades.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 12,500 Shares of StockMay 16 at 7:09 PM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $1,695,375.00 in StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Gary A. Lyons sold 12,500 shares of the company's stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $135.63, for a total value of $1,695,375.00. Following the completion of the transaction, the director now directly owns 116,947 shares of the company's stock, valued at approximately $15,861,521.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.May 16 at 8:35 AM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Principal Financial Group Inc.Principal Financial Group Inc. increased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 10.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 418,245 shares of the company's stock after purchasing anMay 16 at 6:38 AM | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Raised to "Strong-Buy" at Evercore ISIMay 16 at 3:32 AM | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Now Covered by Evercore ISIMay 15, 2024 | marketbeat.comM&G Investment Management Ltd. Acquires 5,781 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)M&G Investment Management Ltd. grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 8.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 73,615 shares of the company's stock after purchasing an additional 5,7May 14, 2024 | nasdaq.comEvercore ISI Group Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform RecommendationMay 14, 2024 | prnewswire.comNeurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024May 14, 2024 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Earns Outperform Rating from Analysts at Evercore ISIEvercore ISI assumed coverage on Neurocrine Biosciences in a report on Tuesday. They issued an "outperform" rating and a $175.00 price target for the company.May 14, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Jump Financial LLCJump Financial LLC increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 114.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,905 shares of thMay 13, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by BNP Paribas Financial MarketsBNP Paribas Financial Markets boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 10.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 307,630 shares of the company's stock afMay 11, 2024 | marketbeat.comVictory Capital Management Inc. Acquires 47,389 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Victory Capital Management Inc. boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 67.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 117,221 shares of the company's stock after buying an additional 47,389 shareMay 10, 2024 | americanbankingnews.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Rating of "Moderate Buy" from AnalystsMay 9, 2024 | finance.yahoo.comHow Neurocrine Is Stacking Up Wins In 2024 — And Outperforming PeersMay 9, 2024 | finance.yahoo.comHow Neurocrine, An IBD 50 Stock, Is Stacking Up Wins In 2024 — And Outperforming PeersMay 9, 2024 | prnewswire.comNeurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024May 9, 2024 | insidertrades.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 273 Shares of StockMay 9, 2024 | prnewswire.comNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy AdultsMay 9, 2024 | globenewswire.comNxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsMay 8, 2024 | marketbeat.comIngrid Delaet Sells 273 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Ingrid Delaet sold 273 shares of the stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $140.55, for a total transaction of $38,370.15. Following the completion of the transaction, the insider now directly owns 7,507 shares of the company's stock, valued at $1,055,108.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.May 8, 2024 | marketbeat.comSawgrass Asset Management LLC Invests $13.12 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Sawgrass Asset Management LLC acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 99,557 shares of the companyMay 8, 2024 | prnewswire.comNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsMay 7, 2024 | marketbeat.comLisanti Capital Growth LLC Trims Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Lisanti Capital Growth LLC cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 74.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,755 shares of the company's stock after selling 19,875 shares during the periodMay 7, 2024 | prnewswire.comNeurocrine Biosciences to Present at the BofA Securities 2024 Health Care ConferenceMay 7, 2024 | prnewswire.comNeurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024May 6, 2024 | prnewswire.comNeurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and MonitoringMay 3, 2024 | markets.businessinsider.comMaintaining Hold on Neurocrine Biosciences Amidst Pipeline Potential and Market Valuation ConcernsMay 3, 2024 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $150.00Citigroup raised their target price on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the stock a "neutral" rating in a research note on Friday.May 3, 2024 | prnewswire.comNeurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024May 2, 2024 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Increased to $164.00 by Analysts at Canaccord Genuity GroupCanaccord Genuity Group increased their price objective on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the company a "buy" rating in a research report on Thursday.May 2, 2024 | marketbeat.comSummit Global Investments Acquires 10,696 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Summit Global Investments grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 35.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 40,733 shares of the company's stock afterMay 2, 2024 | msn.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comNeurocrine Biosciences First Quarter 2024 Earnings: EPS Misses ExpectationsMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Neurocrine Biosciences on Strong Performance and Promising PipelineMay 2, 2024 | finance.yahoo.comNeurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...May 2, 2024 | gurufocus.comQ1 2024 Neurocrine Biosciences Inc Earnings Call TranscriptMay 1, 2024 | finance.yahoo.comNeurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic AdvancementsMay 1, 2024 | nasdaq.comNeurocrine Biosciences Inc Q1 Earnings SummaryMay 1, 2024 | markets.businessinsider.comNeurocrine’s Hold Rating Affirmed Amid Earnings Shortfall and Steady Sales OutlookMay 1, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For Neurocrine BiosciencesMay 1, 2024 | finance.yahoo.comWhy Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% BiotechMay 1, 2024 | investorplace.comNBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024May 1, 2024 | marketbeat.comNeedham & Company LLC Reiterates "Hold" Rating for Neurocrine Biosciences (NASDAQ:NBIX)Needham & Company LLC reaffirmed a "hold" rating on shares of Neurocrine Biosciences in a research report on Wednesday.May 1, 2024 | marketwatch.comNeurocrine Biosciences Posts Higher 1Q Net Product SalesMay 1, 2024 | prnewswire.comNeurocrine Biosciences Reports First Quarter 2024 Financial ResultsApril 30, 2024 | markets.businessinsider.comFDA Approves Neurocrine Biosciences' INGREZZA Sprinkle Capsules Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm. Click here to access the Crypto Retirement Blueprint now. NBIX Media Mentions By Week NBIX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼0.800.43▲Average Medical News Sentiment NBIX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼199▲NBIX Articles Average Week Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Repligen News Today Exelixis News Today Halozyme Therapeutics News Today Denali Therapeutics News Today Adaptive Biotechnologies News Today Biogen News Today Bio-Techne News Today Qiagen News Today Vaxcyte News Today BioNTech News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
